TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02467738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy with Cesium-131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesium-131
Description: Undergo brachytherapy with Cesium-131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Undergo surgical resection
Study: NCT02009436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given via nebulizer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01294202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387 and Imatinib
Description: In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib.
Study: NCT02073175

Intervention type: DRUG
Group type: OTHER
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
Study: NCT02976714

Intervention type: OTHER
Group type: OTHER
Intervention: spontaneous sputum
Description: CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate.
Study: NCT01922687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine plus atorvastatin (Caduet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine (Norvasc)
Study: NCT00642395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib-Melphalan
Study: NCT02215876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
Study: NCT03309085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated CT scan
Description: CT scan of chest on different PEEP levels, 4 in total

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan
Study: NCT01268358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: Lamazym, ERT, infusion weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: Lamazym, ERT, infusion weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: Lamazym, ERT, infusion weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: Lamazym, ERT, infusion weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: Lamazym, ERT, infusion weekly
Study: NCT01981655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5M Sodium lactate
Description: A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's solution
Description: Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
Study: NCT02533063

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibeTech One
Description: Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VibeTech One
Description: Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g.
Study: NCT02595476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tetanic stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algiscan
Description: Pupillometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algiscan
Description: Pupillometry
Study: NCT03850600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-CD
Description: CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
Study: NCT02532881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos
Description: Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual
Study: NCT03754621

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum thyroid functions tests
Description: Serum TSH, fT3, fT4 and anti-TPO
Study: NCT00793897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
Study: NCT03383484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
Study: NCT00530985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits Counseling
Description: Help deciding whether to work

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Orientation
Description: Orientation to services available at VA
Study: NCT00071942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-MUC1 vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-TRICOM vaccine
Description: Given intradermally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02701452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COAGO
Description: blood samples for haemostasis and hormonal data
Study: NCT03728075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES was placed on the quadriceps muscle of both legs
Study: NCT06190652

Intervention type: DRUG
Intervention: Chemotherapy combined with immunotherapy
Description: chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors

Intervention type: DRUG
Intervention: Chemotherapy combined with immunotherapy
Description: chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors

Intervention type: RADIATION
Intervention: radiotherapy
Description: Intensity-modulated radiation therapy
Study: NCT01859728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Study: NCT03804203

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study: NCT03885310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GIE Drug Coated Balloon
Description: The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
Study: NCT03691129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participation in the elderly yoga program
Description: Yoga participant groups will practice elderly yoga for four months.
Study: NCT05818592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Pulse Monitoring
Description: Participants will manually monitor pulse for irregularities.
Study: NCT02427074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Compression Rhizotomy
Description: The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Thermal Coagulation Rhizotomy
Description: The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
Study: NCT01027819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile bearing
Description: Mobile bearing in total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed bearing
Description: Fixed bearing in total knee arthroplasty
Study: NCT01033825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA Nasal Aerosol 320 mcg
Description: Ciclesonide HFA Nasal Aerosol 320 μg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA Nasal Aerosol 160 mcg
Description: Ciclesonide HFA Nasal Aerosol 160 μg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HFA Nasal Aerosol placebo
Description: HFA Nasal Aerosol placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide Aqueous Nasal Spray 200 mcg
Description: Ciclesonide Aqueous Nasal Spray 200 mcg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AQ Nasal Spray Placebo
Description: AQ Nasal Spray Placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Dexamethasone HFA
Description: Dexamethasone capsules 6 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo AQ plus Dexamethasone 6 mg
Description: Placebo AQ plus Dexamethasone 6 mcg capsules once daily
Study: NCT02913690

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 150mg capsules daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRF
Description: 2 x 150mg capsules daily
Study: NCT00755274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine No Preservative: Pediatric Dose
Description: 0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine No Preservative: Pediatric Dose
Description: 0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
Study: NCT01868880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine plus beta-blocker (bisoprolol)
Description: Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betablocker titration
Description: Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
Study: NCT03757286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FSF with CAD\CAM customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FSF without customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed.
Study: NCT02904915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No analgesia
Description: IUD placement without analgesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device (IUD)
Description: IUD placement with or without paracervical block with 1% lidocaine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device (IUD)
Description: IUD placement with or without paracervical block with 1% lidocaine.
Study: NCT03019042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi
Description: Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
Study: NCT01422122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 mg per day, one tablespoon syrup per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one table spoon Syrup per day
Study: NCT00550680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
Study: NCT04020601

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dextrose
Description: Sham injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: Sham injection
Study: NCT03693625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC-0853
Description: Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
Study: NCT02731261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor memory consolidation
Description: Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
Study: NCT04754880

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of oxidative and antioxidative markers between groups
Description: Oxidant and anti-oxidant markers

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of oxidative and antioxidative markers between groups
Description: Oxidant and anti-oxidant markers
Study: NCT03912675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integra® dermal substitute and RigeneraTM protocol
Description: Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integra® dermal substitute and RigeneraTM protocol
Description: Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
Study: NCT02725983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPT consultation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPT consultation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOPROCARE®
Study: NCT02997904

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Apply Liquid Then Comb Out
Description: Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apply Liquid Then Comb Out
Description: Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
Study: NCT01246570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The patients will meet for organized exercise training once monthly and also exercise testing every third month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients will receive the usual care provided by the hospitals and the community health services